{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:02:00Z","timestamp":1781521320958,"version":"3.54.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,6,15]]},"DOI":"10.2169\/internalmedicine.6535-20","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T22:16:24Z","timestamp":1610662584000},"page":"1847-1853","source":"Crossref","is-referenced-by-count":20,"title":["Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab"],"prefix":"10.2169","volume":"60","author":[{"given":"Yuichi","family":"Honma","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Gohda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumiya","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"},{"name":"Department of Pathology, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Miyama","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahori","family":"Morino","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Koya","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"},{"name":"Department of Gastroenterology, Moji Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Taira","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguru","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kusanaga","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Oe","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Abe","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Harada","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348: 56-61, 2015.","DOI":"10.1126\/science.aaa8172"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hack SP, Spahn J, Chen M, et al. IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol 16: 975-989, 2020.","DOI":"10.2217\/fon-2020-0162"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39: 1075-1084, 2015.","DOI":"10.1097\/PAS.0000000000000453"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377: 1345-1356, 2017.","DOI":"10.1056\/NEJMoa1709684"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Haanen JBAG, Carbonnel F, Robert C, et al.; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (Suppl 4): iv119-iv142, 2017.","DOI":"10.1093\/annonc\/mdx225"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Successful treatment of sudden hepatitis induced by long-term nivolumab administration. Case Rep Oncol 10: 368-371, 2017.","DOI":"10.1159\/000471480"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kubo T, Sugawara T, Shinkawa T, et al. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma. Immunol Med 7: 1-6, 2020.","DOI":"10.1080\/25785826.2020.1788229"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20: 924-937, 2019.","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21: 44-59, 2020.","DOI":"10.1016\/S1470-2045(19)30689-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767, 2007.","DOI":"10.1002\/cncr.23099"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 7: e49717, 2012.","DOI":"10.1371\/journal.pone.0049717"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 52: 117-124, 2018.","DOI":"10.1016\/j.semcancer.2017.12.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Riveiro-Barciela M, Barreira-D\u00edaz A, Vidal-Gonz\u00e1lez J, et al. Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors. Liver Int 40: 1906-1916, 2020.","DOI":"10.1111\/liv.14489"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol 71: 665-671, 2018.","DOI":"10.1136\/jclinpath-2018-205143"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68: 1181-1190, 2018.","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 31: 965-973, 2018.","DOI":"10.1038\/s41379-018-0013-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koya Y, Shibata M, Shinohara N, et al. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work. Hepatol Res 49: 950-956, 2019.","DOI":"10.1111\/hepr.13329"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol 72: 320-341, 2020.","DOI":"10.1016\/j.jhep.2019.10.021"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kennedy LB, Salama AKS. A review of immune-mediated adverse events in melanoma. Oncol Ther 7: 101-120, 2019.","DOI":"10.1007\/s40487-019-0096-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM. Grand round: autoimmune hepatitis. J Hepatol 70: 773-784, 2019.","DOI":"10.1016\/j.jhep.2018.11.006"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol 2019: 6391712, 2019.","DOI":"10.1155\/2019\/6391712"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/12\/60_6535-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T16:54:53Z","timestamp":1670777693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/12\/60_6535-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6535-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}